Warner Chilcott
Trial Pipeline
A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy
NCT02670785
Evaluate Long-Term Safety and Efficacy WC3011 (Estradiol Vaginal Cream)
NCT01455597
Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women
NCT01400776
Treatment of Erectile Dysfunction II
NCT01037218
Treatment of Erectile Dysfunction I
NCT01037244
Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women
NCT00918749
Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects
NCT00699777
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
NCT00541658
Fecal Biomarker Study for Patients With Ulcerative Colitis
NCT00780507
A Comparison of Once a Day Dose Compared to 2 Doses/Day
NCT00505778
Study of Safety and Efficacy of an Oral Contraceptive
NCT00477633
Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate
NCT00577720
A Study of Monthly Risedronate for Osteoporosis
NCT00247273
Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
NCT00106028
Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD
NCT00577837
Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate
NCT00778154
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
NCT00577850
Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
NCT00349791
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
| Phase 3 | 10 |
What the Pipeline for Warner Chilcott Shows
According to the ClinicalTrials.gov registry, Warner Chilcott is linked to 18 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 18 are already marked complete, representing roughly 100% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Warner Chilcott reports 10 late-stage studies (Phase 3 and Phase 4 combined) and 6 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Warner Chilcott is Postmenopausal Osteoporosis with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.